Strategic AI collaboration with Inceptive
Research partnerships Announcement
Disclosed: Verified: Partners: Inceptive Nucleics, Inc.
Alnylam and Inceptive Nucleics announced a strategic collaboration, valued at up to $2B with upfront consideration of $30M, pairing Alnylam's RNAi platform and proprietary siRNA data with Inceptive's foundation models and AI expertise to accelerate nucleic-acid drug design.
up to $2B company-reported
Source
Joint release Archive pending